KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to 33.1%.

  • Emergent BioSolutions' EBIT Margin rose 111500.0% to 33.1% in Q3 2025 from the same period last year, while for Sep 2025 it was 15.02%, marking a year-over-year increase of 305500.0%. This contributed to the annual value of 10.42% for FY2024, which is 588100.0% up from last year.
  • Latest data reveals that Emergent BioSolutions reported EBIT Margin of 33.1% as of Q3 2025, which was up 111500.0% from 1.14% recorded in Q2 2025.
  • Emergent BioSolutions' EBIT Margin's 5-year high stood at 39.13% during Q4 2021, with a 5-year trough of 407.0% in Q2 2024.
  • Moreover, its 5-year median value for EBIT Margin was 4.88% (2024), whereas its average is 32.46%.
  • Per our database at Business Quant, Emergent BioSolutions' EBIT Margin plummeted by -3203200bps in 2024 and then soared by 4081400bps in 2025.
  • Over the past 5 years, Emergent BioSolutions' EBIT Margin (Quarter) stood at 39.13% in 2021, then tumbled by -143bps to 16.75% in 2022, then grew by 5bps to 15.84% in 2023, then surged by 69bps to 4.88% in 2024, then surged by 778bps to 33.1% in 2025.
  • Its EBIT Margin was 33.1% in Q3 2025, compared to 1.14% in Q2 2025 and 22.46% in Q1 2025.